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Abstract Glioblastoma cell cultures in vitro are fre-
quently used for investigations on the biology of tumors or
new therapeutic approaches. Recent reports have empha-
sized the importance of cell culture type for maintenance
of tumor original features. Nevertheless, the ability
of GBM cells to preserve EGFR overdosage in vitro
remains controversial. Our experimental approach was
based on quantitative analysis of EGFR gene dosage in
vitro both at DNA and mRNA level. Real-time PCR data
were verified with a FISH method allowing for a distinc-
tion between EGFR amplification and polysomy 7. We
demonstrated that EGFR amplification accompanied by
EGFRwt overexpression was maintained in spheroids, but
these phenomena were gradually lost in adherent culture.
We noticed a rapid decrease of EGFR overdosage already
at the initial stage of cell culture establishment. In contrast
to EGFR amplification, the maintenance of polysomy 7
resulted in EGFR locus gain and stabilization even in long-
term adherent culture in serum presence. Surprisingly, the
EGFRwt expression pattern did not reflect the latter phe-
nomenon and we observed no overexpression of the tested
gene. Moreover, quantitative analysis demonstrated that
expression of the truncated variant of receptor—EGFRvIII
was preserved in GBM-derived spheroids at a level com-
parable to the initial tumor tissue. Our findings are espe-
cially important in the light of research using glioblastoma
culture as the experimental model for testing novel EGFR-
targeted therapeutics in vitro, with special emphasis on the
most common mutated form of receptor—EGFRvIII.
Keywords Glioblastoma  Cell cultures  Spheroids 
EGFR amplification  EGFRvIII
Introduction
One of genetic hallmarks of glioblastoma (GBM) is EGFR
(epidermal growth factor receptor) gene amplification,
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occurring in 30–40% of primary GBM [1, 2]. This
alteration is regarded as an in vivo phenomenon difficult
to sustain in vitro in glioblastoma-derived, traditional cell
cultures. Therefore, the genetically modified GBM cell
lines with artificial EGFR gene aberrations and xenograft
technology became alternative models for analyses
requiring EGFR overdosage [3–5]. In addition, numerous
GBMs present rearrangements and mutations of EGFR
gene. EGFRvIII (EGFR.D2–7) is the most common
mutated variant characterized by a truncation of 267
amino acids within the extracellular domain of the pro-
tein, resulting in a constitutive activity of the receptor
[6]. Aberrant signaling induced by EGFR gene over-
dosage or mutations makes epidermal growth factor
receptor an interesting target for therapeutic investiga-
tions with a special emphasis on EGFRvIII [7, 8].
Glioblastoma cell cultures are frequently used for
investigations targeted at the biology of the tumor, or for
searching for new therapeutic approaches. However, recent
reports have emphasized the importance of cell culture type
and conditions for the maintenance of genetic profile of
original tumors [9–13]. The comparison of molecular
characteristics of GBM cells in vitro revealed differences
between spheroids and monolayer cell culture, indicating
spheroid cultures as the best tool in which the original
genetic profile of the tumor is preserved [11]. This finding
seems to be consistent with our previous data suggesting
that GBM-derived spherical aggregates are able to main-
tain certain molecular and phenotypic features of primary
cancer cells [14].
The priority of our present investigation was to evaluate
the status of EGFR gene, including EGFRvIII, as the most
common mutated variant in GBM cells cultured as either
spherical aggregates/spheroids or monolayer.
Materials and methods
Cell culture
Glioblastoma samples
Tumor samples were obtained from patients with GBM who
underwent neurosurgery at the following hospitals: Depart-
ment of Neurosurgery, Polish Mother’s Memorial Hospital,
Lodz; Department of Neurosurgery, Medical University of
Lodz; Department of Neurosurgery, Copernicus Hospital,
Lodz, Poland. All samples were collected under protocols
approved by the ethical committee of Medical University of
Lodz. The diagnosis was made by histopathology and, when
appropriate, immunohistochemistry.
Establishment and growth of adherent glioblastoma cell
cultures
The tumor cells were dispersed by means of collagenase
type IV (200 u/ml, 37C for 6 h). Subsequently, the cells
were cultured in aMEM medium containing 10% FBS
(Gibco). Depending on proliferation activity, the cells were
passaged to new culture dish every 3–10 days.
Establishment and growth of spheroid glioblastoma cell
cultures
The tumor cells were dispersed by means of collagenase
type IV (200 u/ml, 37C for 6 h). Subsequently, the cells
had been cultured for 12 h in expansion medium (aMEM
with 10% FBS), then the medium was changed to the
serum-starvation medium. The obtained spherical aggre-
gates were isolated after 1–4 days of incubation and
transferred to the cell culture dishes covered with Matrigel
(BD Biosciences) and cultured in Neurobasal serum-free
medium supplemented with N2 and B27 (0.59 each;
Invitrogen) with addition of human recombinant bFGF and
EGF (50 ng/ml each; Invitrogen). The aggregates were
cultured up to 8–12 weeks, and transferred every
5–15 days.
BrdU incorporation assay
To assess the proliferation of glioblastoma cells in culture,
10 lM BrdU (Sigma), a marker of DNA synthesis, was
added to the cells cultured as spherical aggregates and
subsequent passages of adherent culture. After 48 h of
incorporation, the tested cultures were processed for
immunocytochemistry. For BrdU staining, immunocyto-
chemistry was performed according to the manufacturer’s
protocol with the use of primary antibodies (mouse anti-
BrdU, 1:500; Sigma) and secondary antibodies (donkey
anti-mouse AlexaFluor594, 1:250; Molecular Probes).
Then, the slides were treated with the ProLong Gold
Antifade Reagent (Molecular Probes), coverslipped and
examined, using an Olympus BX-41 fluorescence
microscope.
EGFR gene dosage analysis at DNA and mRNA level
DNA and RNA isolation
For molecular analyses, DNA and RNA were isolated
simultaneously with the use of AllPrep DNA/RNA Mini
kit (Qiagen) from original tumor samples, subsequent
passages of adherent cell cultures and spherical aggregates
at the final stage of their culture.
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Quantitative real-time PCR at DNA level
To determine the EGFR gene dosage level in original
tumor tissue, cells cultured as spheroids, and monolayer,
quantitative real-time PCR was performed using Rotor-
Gene 6000 instrument (Corbett Life Science). The fol-
lowing EGFR primers were used for amplification:
F: AACCATGCCCGCATTAGCTC; R: AAAGGAATGC
AACTTCCCAA.
Each sample was amplified in triplicate in a reaction
volume of 10 ll containing 50 ng of DNA, 19 reaction
mix with Syto9 (Invitrogen) and forward and reverse pri-
mer, 35 ng each. The cycling conditions were as follows:
3 min at 95C (polymerase activation) followed by 40
cycles of 20 s at 95C (denaturation), 30 s at 60C
(annealing) and 1 min at 72C (extension).
RNase P was used as a reference gene for normalization
of the target gene dosage level. To confirm the specificity
of the amplification signal, the gene dissociation curve was
considered in each case. The normalized relative EGFR
gene dosage level of the tested samples versus control
sample was calculated utilizing the method described
previously by Pfaffl et al. [15], based on each sample’s
average CT value and each gene’s average PCR efficiency.
As a control sample, DNA derived from non-tumoral tissue
(leukocytes) was used, on the assumption that the gene
dosage in normal tissue would be 1. The values higher than
2 were considered as overdosage of the tested gene.
Quantitative real-time RT-PCR
Reverse transcription was performed using QuantiTect
reverse transcription kit (Qiagen) according to the manu-
facturer’s protocol. Real-time PCR was performed using
RotorGene 6000 instrument (Corbett Life Science).
EGFRwt- and EGFRvIII-specific primers were used for
amplification of the tested genes. GUSB was used as a
reference gene for normalization of the target gene
expression level. The primers data were based on previous
reports [16, 17]. Each sample was amplified in triplicate in a
reaction volume of 10 ll containing 50 ng of cDNA, 19
reaction mix with Syto9 and forward and reverse primer,
35 ng each. The cycling conditions were as follows: 3 min
at 95C (polymerase activation) followed by 40 cycles of
20 s at 95C (denaturation), 30 s at 60C (annealing) and
1 min at 72C (extension). To confirm the specificity of the
amplification signal, the gene dissociation curve was con-
sidered in each case. Normalized relative expression level
of EGFRwt or EGFRvIII gene in the tested samples versus
control sample was calculated utilizing the method descri-
bed previously by Pfaffl et al. [15], based on each sample’s
average CT value and each gene’s average PCR efficiency.
In the case of EGFRwt expression analysis, the cDNA
derived from normal human astrocytes (NHA, Lonza, for-
merly Cambrex) was used as a control sample. To evaluate
EGFRvIII expression, cDNA derived from tumor tissue
positive for EGFRvIII was used as a control.
The real-time PCR was preceded by conventional RT-
PCR applied to examine the tested tumor samples in terms
of EGFRvIII expression. The results were obtained with the
use of two pairs of primers described previously [16], and
visualized on agarose gel.
Fluorescence in situ hybridization (FISH)
A commercial probe set (LSI EGFR SpectrumOrange/CEP 7
SpectrumGreen, no 32-191053; Vysis) was used for simul-
taneous determination of the EGFR gene and chromosome 7
copy numbers. FISH was performed in the following way:
the fixed slides were incubated in 29 standard saline citrate
(SSC) at 72C for 5 min. The slides were then placed in 70,
85 and 100% ethanol for 1 min each, air-dried and placed on
a 50C slide warmer for 2 min. The FISH probe set mix (1 ll
LSI DNA probe mix, 7 ll LSI Hybridization Buffer and 2 ll
water) was centrifuged and denatured at 73C for 5 min. The
denatured probe was placed in each specimen. The slides
were then coverslipped and incubated at 37C overnight in a
humidified chamber. Afterwards, the slides were washed
with 0.4x SSC/0.3% NP-40 at 73C for 15 min and rinsed in
29 SSC/0.1% NP-40. 10 ll of DAPI II counterstain were
placed on the slides and coverslipped. For the scoring,
an Olympus BX-41 fluorescence microscope was used,
equipped with a specially designed filter combination for
green and orange spectra.
The number of red signals, corresponding to the EGFR-
specific probe, is directly related to the number of copies
of EGFR. The number of green signals, corresponding to
the centromeric region of chromosome 7, is directly related
to the number of copies of chromosome 7.
FISH evaluation was performed according to previously
published criteria [1]. The EGFR/CEP 7 ratio was calcu-
lated. Ratios of 2 and greater were considered amplified.
Ratios less than 2 were considered nonamplified. Polysomy
7 was defined as the nuclei contained three or more signals
specific for CEP 7.
Immunocytochemistry
For immunocytochemical analysis, cell cultures were fixed
for 15 min in 4% paraformaldehyde in PBS (and perme-
abilized with 0.1% Triton X-100 for 10 min for SOX2
detection). Nonspecific binding sites were blocked with 2%
donkey serum in PBS for 1 h. Subsequently, the cells were
incubated for 1 h with the following antibodies: rabbit
polyclonal antibody against SOX2 (1:1,000, Chemicon) or
mouse monoclonal antibody against EGFR (528) (1:100;
J Neurooncol (2011) 102:395–407 397
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Santa Cruz Biotechnology). For visualization, the appro-
priate species-specific fluorochrome-conjugated secondary
antibodies (1:250, donkey anti-rabbit AlexaFluor488,
1:250, donkey anti-mouse Alexa-Fluor594; Molecular
Probes) were applied for 1 h in dark. Controls with sec-
ondary antibodies alone, and with matched isotype controls
in place of primary antibodies were processed in the same
manner. Slides were mounted with ProLong Gold Antifade
Reagent with DAPI (Molecular Probes), coverslipped and
examined using an Olympus BX-41 fluorescence microscope.
Invasion assay
The invasion assay was performed with the use of Matrigel
invasion chambers (BD Biosciences) according to manu-
facturer’s protocol. To investigate the invasion potential of
GBM-derived spheroids versus adherent cells, the cultures
were established from tumor tissue originally showing
EGFR overdosage (amplification). The spheroids and
adherent cells were cultured according to protocols pre-
sented above up to 3–4 weeks (passage 5 of adherent cul-
ture). Then, the cells were plated in the top well of
prehydrated Matrigel invasion chambers at a density of 2 9
104 cells/well or respectively 10 spheroids/well in DMEM
supplemented with 0.1% FBS (the number of cells in
spheroids was assessed according to criteria published pre-
viously [18]). The bottom wells were provided with DMEM
supplemented with 10% FBS. Cells were allowed to invade
for 40 h. Afterwards, the cells from the top of the chambers
were removed and the filters were fixed in 4% paraformal-
dehyde (Sigma) in PBS for 15 min and subsequently stained
fluorescently with DAPI. Invasion was quantified by count-
ing of the cell number on the underside of the filter from 3
fields using an Olympus BX-41 fluorescence microscope.
The data were expressed as the average number (means ±
SD) of cells from 3 fields that invaded to the lower surface of
the filter from each of 4 experiments performed.
Alternative approach to verify invasion ability of
spheroids was applied according to simplified method
described previously [19].
The GBM-derived spheroids were implanted and cul-
tured into three-dimensional Matrigel. The invasion pro-
cess was monitored using an inverted microscope
(Olympus) and visualized as photomicrographs.
Statistical analysis
The real-time PCR data were expressed as the means ±
SD. The invasion results were expressed as the average
number (means ± SD) of cells from 3 fields that invaded
to the lower surface of the filter from each of 4 experiments
performed. The data were analyzed by nonparametric
methods. When more than two groups were analyzed, the
Kruskal–Wallis test was used, initially to identify a dif-
ference and, if this proved significant, individual groups
were further investigated using Conover–Inman, a non-
parametric posthoc test. In order to compare two groups,
the Mann–Whitney U test was used. In all tests, P \ 0.05
was considered significant.
Results
Establishment and basic characteristics of glioblastoma
cell cultures derived from the tumors presenting
increased EGFR gene dosage
Initially, the 13 samples of GBM were examined for EGFR
gene dosage using real-time PCR. Those GBM samples
with clear EGFR overdosage (values describing relative
EGFR dosage above 2) were further used for cell cultures
establishment (G1, G16, G32, G33, G48, G54; Fig. 1).
Cells derived from the selected tumors were cultured as
monolayer and spherical aggregates/spheroids (Fig. 2)
either in the presence of serum or in serum-free conditions,
depending on their inherent tendency to adherent or a
spherical growth. The serum-free medium was the factor
most favorable to spherical aggregates, which could be
propagated in these conditions up to 3 months reaching the
size of 200–500 lm depending on particular examined
tumors. The attempts to propagate spherical aggregates
in a presence of serum led to dispersal of the cells in a short
time.
The G1-, G32-, G48-, and G54-derived cells were grown
as a short-term adherent cultures until passage 10th at most
(8–12 weeks), by which time they became senescent. The
long-term cultures were obtained from G16 and G33
tumors (20–24 weeks). The cultures were terminated at the
passage 25 for G33 and the passage 50 for G16, although
Fig. 1 Initial evaluation of EGFR gene dosage in glioblastoma
tumors. Results of real-time PCR (means ± SD) allowed the
identification of GBMs exhibiting EGFR overdosage (values describ-
ing relative EGFR dosage above 2)
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those cells presented no features of senescence. BrdU
incorporation assay confirmed that proliferation was
maintained within the spherical aggregates during the
whole period of culture, in contrast to short-term adherent
culture derived from the majority of tested tumors (G1,
G32, G48, G54), except for G16- and G33-derived cells,
which showed proliferative activity even in long-term
monolayer cultures (Fig. 3).
Additionally, the proliferative and differentiation
potential of GBM cells in vitro was examined with the use
Fig. 2 Spheroid and adherent
cultures of GBM-derived cells.
Light photomicrographs
presenting the cells derived
from the selected tumors with
EGFR overdosage cultured as
spherical aggregates and
monolayer
Fig. 3 Proliferation ability of
GBM-derived culture in vitro
assessed with BrdU. a The
spherical aggregates obtained
from tumors showing EGFR
amplification demonstrated
maintained proliferation ability
during the whole period of
culture (up to 8–12 weeks).
b The short-term adherent
cultures derived from GBMs
with EGFR amplification
showed gradual decrease of
proliferative activity to a very
low level at the final stage of
culture (8–12 weeks). c The
proliferation ability was
sustained even in long-term
adherent cultures derived from
tumors showing polysomy 7 (up
to 20–24 weeks)
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of SOX2 status analysis in spheroids and monolayer. The
immunocytochemistry assay demonstrated gradual silenc-
ing of SOX2 expression in subsequent passages of adherent
cells in contrast to spheroids showing ability to maintain
high level of SOX2 protein (Fig. 4).
The basic characteristics of tumors selected for further
analysis are presented in Table 1. Spherical aggregates and
successive passages of adherent cells were used for further
investigations, including analyses of EGFR gene dosage
status at DNA and mRNA level.
Comparative quantification of EGFR status in GBM cells
in vitro was performed for the following cell populations at
different stages of culture: G1, G32, G48—passage 0
(0–1 week), passage 5 (3–4 weeks), passage 10 (8–12 weeks),
spheroids (8–12 weeks); G16, G33—low passages described
as short-term culture (0–12 weeks) versus high passages
described as long-term culture (16–24 weeks).
EGFR gene dosage status in adherent and spheroid
cultures of glioblastoma cells
The samples with clearly visible EGFR overdosage (G1,
G16, G32, G33, G48) were verified by FISH technique that
revealed amplification of the tested gene in three cases
(G1, G32, G48) and polysomy of chromosome 7 and
EGFR locus in two cases (G16, G33) (Fig. 5). In the cases
of G1, G32 and G48 samples, the single cells with low
polysomy 7 were also observed; nevertheless, their pres-
ence did not influence further quantitative analyses. EGFR
amplification was a dominant feature in these samples, thus
they were classified as EGFR-amplified GBMs. Subse-
quently, real-time PCR technique was applied to monitor
the status of EGFR gene dosage in selected GBM-derived
cultures. Quantitative analysis revealed two patterns of
EGFR gene dosage changes in the consecutive passages of
Fig. 4 Proliferative and
differentiation potential of
GBM cells in vitro evaluated
with SOX2 expression.
Immunocytochemistry data
demonstrated a ability of
spheroids to maintain SOX2
expression, and b gradual loss
of this neural stem cell marker
in adherent culture
Table 1 Characteristics of GBM-derived cultures presenting EGFR overdosage
GBM Adherent culture lengtha Spherical aggregates EGFR status EGFRvIII
G1 Short-term (p0–p10) Yes Amplification No
G16 Long-term (p0–p50) No Polysomy 7 and EGFR locus No
G32 Short-term (p0–p5) Yes Amplification No
G33 Long-term (p0–p25) No Polysomy 7 and EGFR locus No
G48 Short-term (p0–p10) Yes Amplification Yes
G54 Passage 0 only No Non verified No
a Short-term culture (up to 8–12 weeks at most); long-term culture (up to 20–24 weeks at most)
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adherent cultures. The short-term monolayer cultures,
derived from the tumors with EGFR amplification (G1,
G32, G48), showed a gradual decrease of EGFR gene
dosage (Fig. 6a). In contrast, two long-term cultures
derived from GBMs with polysomy 7 (G16, G33) showed a
gain of EGFR dosage at higher passages (Fig. 6b). The
analysis of consecutive passages of G16 and G33 suggested
a stabilization of EGFR dosage level at the final stage of
the culture (data not shown).
Further analysis of EGFR amplification status in GBM
cells in vitro revealed no significant changes of gene dos-
age in the initial cell culture and subsequently derived
spherical aggregates in a case of G1 and G32. G48-derived
spheroids, compared to the passage 0, showed a modest
decrease of EGFR dosage; nevertheless, they were still able
to maintain EGFR amplification at a level higher than the
adherent cells (Fig. 6a). However, the comparison of
EGFR amplification status in original tumors and cell
cultures revealed a rapid decrease of EGFR amplification
level already at the initial stage of the culture (p0), eliciting
that the EGFR dosage in spheroids was similar to that in
cells at passage 0, but significantly lower when compared
to the original tumor tissue (Fig. 6c).
Expression pattern of EGFRwt and EGFRvIII at mRNA
level in GBM-derived cultures in vitro
Quantitative real-time PCR analysis revealed overexpres-
sion of EGFRwt in samples showing EGFR amplification
(G1, G48), followed by a gradual downregulation of the
tested gene in adherent cultures in the serum presence and
maintenance of high level of EGFRwt mRNA in spheroids
(Fig. 7a). The cell cultures derived from those tumors
showing polysomy 7 (G16, G33) presented distinct pat-
terns of EGFRwt expression. However, in both cases,
EGFRwt overexpression was not observed. The G16-
derived cells showing polysomy 7 expressed EGFRwt at a
level similar to the control (NHA) in long-term cultures,
while the lower passages demonstrated a decreased
expression of the tested gene. The G33-derived cells
showed underexpression of EGFRwt irrespective of culture
length (Fig. 7b).
Additionally, the selected tumors showing EGFR over-
dosage were evaluated in terms of EGFRvIII presence. On
Fig. 5 Verification of EGFR gene dosage status with the use of FISH
method. FISH with an EGFR probe (red signals) and 7q control probe
(green signals) confirmed EGFR overdosage in selected GBMs and
allowed a distinction between amplification of the tested gene and
polysomy 7. G1, G32, and G48 were recognized as samples showing
EGFR amplification (accompanied by low polysomy 7 in single
cells). G16 and G33 were assessed as GBMs with polysomy 7. EGFR
amplification was observed as homogenous or clustered distribution
of EGFR signals in cells with EGFR/CEP7 ratio [ 2 (representative
cells in circles). Polysomy 7 was detected as the nuclei contained
three or more signals specific for CEP 7 (representative cells in
rectangles). EGFR gene amplification and polysomy 7 was scored as
negative if only 2 red signals (EGFR)/2 control green signals (CEP7)
were observed
c
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the basis of RT-PCR results, only one sample (G48) was
classified as EGFRvIII-positive (Fig. 8a). Quantitative
analysis of EGFRvIII expression pattern demonstrated a
rapid decrease of mRNA level in adherent cells and lack of
significant changes in spherical aggregates in comparison
to the tumor tissue. However, in contrast to EGFRwt,
EGFRvIII level was similar in the tumor tissue and the
initial cell culture (Fig. 8b).
Invasive capability of GBM cells cultured as spheroids
and monolayer
The GBM-derived cells presenting EGFR overdosage
(amplification) in original tumor tissue were used to
establish the spheroid and adherent cell cultures. The cells
in spheroids and monolayer were cultured up to 3–4 weeks.
To assay the invasion capability of cells cultured as
spheroids versus adherent cells in vitro the Matrigel-coated
invasion chambers were applied (BD Biosciences). The
quantitative analysis showed significant difference between
the cells number invaded through the Matrigel from
spheroids (55.25 ± 15.18) in comparison to the cells
number invaded from monolayer (11.42 ± 1.07); P = 0.03
(Fig. 9a). The higher invasiveness of the cells cultured in
spheroids versus adherent cells was visualized as fluores-
cent microphotographs of the lower surface of the filters
(Fig. 9b). The immunocytochemistry data demonstrated
that decrease of invasiveness observed in monolayer was
parallel to downregulation of EGFR protein level detected
in adherent cells (passage 5, 3–4 weeks of culture) in
comparison to spheroids (3–4 weeks of propagation)
(Fig. 9c).
In order to confirm the invasiveness of spheroids, an
alternative experimental approach was applied based on the
three-dimensional invasion assay performed previously by
Stein et al. [19]. We showed that the GBM-derived
spheroids implanted into Matrigel were able to release the
cells from the core. As a result, we observed the cells
invading radially into Matrigel and creating the extending
invasive rim around the spheroid core (Fig. 9d).
Fig. 6 Quantitative analysis of EGFR gene dosage at DNA level. a
The short-term monolayer cultures derived from the tumors
presenting EGFR amplification (G1, G32, G48) showed gradual
decrease of EGFR gene dosage, in contrast to spherical aggregates
able to maintain EGFR amplification at a level higher than the
adherent cells. b The long-term cultures derived from GBMs with
polysomy 7 (G16, G33) showed a gain in EGFR dosage at higher
passages. c The initial culture demonstrated a rapid decrease of
EGFR amplification level in comparison to the original tumor
tissue. Real-time PCR data were presented as means ± SD;
P \ 0.05 was considered significant
c
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Discussion
According to Gu¨nther et al. [20], GBM-derived cell cultures
exhibit an inherent ability either to form spherical aggre-
gates/spheroids or a tendency to adherent growth. Our re-
sults, consistent with this scenario, form the basis for a
comparative analysis of a certain molecular and phenotypic
features of spheroid and adherent cultures of GBM cells.
Our initial data based on BrdU assay revealed differences
in a proliferation ability of GBM cells cultured as spherical
aggregates and monolayer, indicating spheroids as the
method of a choice for maintenance of the culture. In con-
trast, the majority of GBM-derived cultures presented pro-
gressive features of senescence under the routine growth
conditions. The different proliferative potential of GBM
spheroids and adherent cultures examined was additionally
emphasized by discrepant expression of SOX2 recognized as
a factor necessary for the continuous proliferation of human
glioma cells [21]. Moreover, regarding SOX2 as a neural
stem cell marker, we can suppose that spheroids and adherent
cells have distinct differentiation status. This suggestion
seems to confirm our previous findings demonstrating mul-
tilineage phenotype and differentiation potential of GBM
cells cultured as spheroids [14].
Fig. 7 Quantitative analysis of EGFRwt expression at mRNA level.
a The tumors with EGFR amplification (G1, G48) showed EGFRwt
overexpression, followed by downregulation of the tested gene in
adherent culture and maintenance of high level of EGFR mRNA in
spheroids. b The cell cultures derived from tumors showing
polysomy 7 showed EGFRwt expression at a level similar to control
(NHA) in long-term culture (G16), or underexpression of EGFRwt
irrespective of the culture length (G33). Real-time PCR data were
presented as means ± SD; P \ 0.05 was considered significant
Fig. 8 EGFRvIII expression pattern in G48-derived cell culture. a
RT-PCR results carried out with two pair of primers (P1 amplicon
size: 131 bp; P2 amplicon size: 90 bp), singled out G48 as EG-
FRvIII-positive sample; C(-) negative control; MW molecular weight
marker. b Quantitative analysis demonstrated a rapid decrease of
EGFRvIII mRNA level in adherent culture at passages 5 and 10, in
contrast to spherical aggregates showing EGFRvIII expression at a
level similar to the tumor tissue and passage 0. Real-time PCR data
were presented as means ± SD; P \ 0.05 was considered significant
J Neurooncol (2011) 102:395–407 403
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Fig. 9 Invasion ability of GBM
spheroids and adherent cells in
vitro. a, b The results of
comparative invasion assay for
spheroid and monolayer
cultures established from the
tumor tissue originally showing
EGFR amplification with the
use of Matrigel invasion
chambers. a Quantitative data
demonstrated decreased
invasiveness of GBM cells in
monolayer in comparison to
spheroids (P = 0.03). b The
cells invaded through the
Matrigel-coated filters were
fluorescently stained with
DAPI. c The
immunocytochemistry data
demonstrated downregulation of
EGFR protein level in adherent
cells in comparison to
spheroids, a phenomenon
parallel to the decrease of
invasiveness. d Visualization of
three-dimensional invasion
assay for spheroids.
Photomicrogarphs of spheroids
implanted into Matrigel at day 1
and day 4 of the culture
presented the cells invaded
radially from the spheroid core
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These observations are consistent with several recent
reports emphasizing the influence of cell culture type and
conditions for the maintenance of the primary features of
original tumors [9–13].
Furthermore, we focused on a quantitative analysis of
EGFR status, including EGFRvIII, both at the DNA and
mRNA levels in GBM-derived cell cultures, since the
available published data did not specify this issue. The
reports of Lee et al. [9] and De Witt Hamer et al. [11]
allowed spheroid cultures and serum-free conditions to be
identified as factors favorable for the stability of the ori-
ginal tumor profile, including gene copy number anoma-
lies. In order to conserve the molecular profile of original
tumors in vitro, Fael Al-Mayhani et al. established the
protocol based on combination of spheroid and monolayer
culture techniques. However, such an experimental strat-
egy did not allow for EGFR amplification maintenance,
despite the successful preservation of other genomic
abnormalities of GBM [13].
Previous reports have shown that EGFR gene overdos-
age is gradually lost in adherent GBM-derived cultures
under routine conditions [4, 11, 22]. Our results confirmed
these findings, demonstrating progressive loss of EGFR
amplification followed by EGFRwt downregulation in
GBM adherent cultures. In contrast to the EGFR amplifi-
cation, polysomy 7 resulted in the EGFR locus gain and
stabilization in long-term GBM culture, even in the pres-
ence of serum. Surprisingly, the EGFRwt expression pat-
tern did not conform to the latter scenario and we observed
no overexpression of the tested gene at the mRNA level.
The data mentioned above called our attention to an
additional aspect of the experiments aimed at EGFR gene
dosage status. In several reports, evaluation of EGFR gene
amplification was based exclusively on quantitative tech-
niques (differential PCR or real-time PCR) that enable
detection of gene gain only. However, our results empha-
sized the importance of the distinction between EGFR
amplification and polysomy 7 as two different mechanisms
of EGFR overdosage. Such an inherent molecular hetero-
geneity of GBM may cause difficulties in quantitative
analysis due to the fact that the low percentage of cells
showing EGFR amplification may yield results indistin-
guishable from polysomy 7 and EGFR locus. Thus, the
unequivocal identification of one of these two phenomena
requires analysis at a single cell level (e.g. FISH technique).
We have also shown that EGFR amplification and EG-
FRwt overexpression are indeed sustained in spheroids.
However, this fact is only partially consistent with previous
reports suggesting the ability of spheroids to preserve pri-
mary profile of tumor [9–11]. The precise quantitative
analysis revealed that, although the spheroids presented
higher EGFR gene dosage than adherent cultures, that
dosage was significantly lower in a comparison to parental
tumor tissue. This phenomenon has never been noted in
previous reports. We speculate that the initial steps of
tumor processing and cell culture establishment are
responsible for the observed phenomenon, and further
research is needed to eliminate this unwelcome effect.
Unfortunately, we found only a single case of GBM
showing the presence of EGFRvIII variant. Surprisingly,
the evaluation of EGFRvIII status in GBM culture dem-
onstrated that the expression of the truncated form of the
receptor was preserved in spheroids at a level comparable
to the initial tumor tissue. In contrast, it was completely
lost in the adherent culture.
Our findings are potentially significant in the context of
research using tumor spheroid cultures as an experimental
model for testing novel therapeutics [23, 24]. Also, several
recent investigations have been focused on the truncated
variant of receptor—EGFRvIII, as a putative therapeutical
target [25]. In addition, a report of Martens et al. [26]
suggests that responsiveness of the tumor to certain ther-
apeutics is conditioned by the presence of EGFRvIII and
dependent on the EGFR amplification status.
It is noteworthy that our experimental approach assumes
the use of GBM spheroids derived from parental tumors
showing EGFR overdosage or mutational aberration in
vivo. Such an approach may offer an alternative way for
analyses based on genetically modified glioblastoma cell
lines presenting artificial EGFR gene anomalies [27, 28].
Tumor cell lines are unified models devoid of characteristic
features specific to individual tumors. This issue seems not
to be trivial, especially because of recent reports suggesting
the benefits of personalized cancer treatment adjusted to
the molecular profile and phenotype of a particular tumor
[8, 29, 30].
Moreover, our results revealing a decreased invasion
potential of adherent GBM cells in vitro accompanied by
the decline in EGFR expression and capability of spheroids
to maintain both of these features seem to be consistent
with previous findings suggesting the influence of epider-
mal growth factor receptor on the invasiveness of tumor
cells [19, 31, 32].
In conclusion, our findings confirm that GBM-derived
spheroids seem to be a promising tool to preserve original
molecular features of the tumor in vitro with a special
emphasis on EGFR gene aberrations, including EGFRvIII,
regarded as novel therapeutic target. Moreover, it is worth
considering whether it is possible to create an alternative
experimental model on the basis of long-term GBM culture
presenting EGFR gain as a result of polysomy 7. However,
in this case, further research is needed in order to achieve
EGFR overexpression in vitro.
Finally, the reasons underlying the loss of EGFR
anomalies in vitro remain a matter of debate. Identification
of the underlying mechanisms may also aid the creation of
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new therapeutic approaches targeted at those cancers
showing EGFR aberrations, particularly since GBM cells
exhibiting EGFR amplification/overexpression and
EGFRvIII presence are regarded as the aggressive and
invasive population [7, 33, 34].
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